MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-30-2026
Country |
 France |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
140 M |
Market Cap[1] |
$ 2.58 B |
EBITDA (LTM) |
$ -83 M |
P/E (LTM) |
-19.49 |
P/S (LTM) |
642.04 |
EPS (LTM) |
-1.0 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market |  Canada |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
- | 1.35 % | $ 17.8 M | Nasdaq Capital Market |  China |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American |  USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market |  Israel |
 |
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Esperion Therapeutics
ESPR
|
$ 3.14 | 0.32 % | $ 653 M | Nasdaq Global Market,SPB | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 35.15 | 2.02 % | $ 946 M | Nasdaq Global Market | USA |
|
Forte Biosciences
FBRX
|
$ 21.32 | 4.95 % | $ 276 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market |  Belgium |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.07 | -1.4 % | $ 5.48 B | Nasdaq Global Select Market |  Spain |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | USA |
 |
IMV
IMV
|
- | - | $ 13.1 M | Nasdaq Global Select Market | Canada |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
BioNTech SE
BNTX
|
$ 90.64 | 0.3 % | $ 21.9 B | Nasdaq Global Select Market | Germany |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.65 | 1.54 % | $ 439 M | Nasdaq Global Select Market | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Heron Therapeutics
HRTX
|
$ 0.85 | 0.96 % | $ 142 M | Nasdaq Global Select Market,SPB | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | USA |
 |
Incyte Corporation
INCY
|
$ 96.88 | -0.21 % | $ 18.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Compugen Ltd.
CGEN
|
$ 2.6 | -3.88 % | $ 243 M | Nasdaq Global Market,SPB | Israel |
 |
Ionis Pharmaceuticals
IONS
|
$ 75.36 | 0.39 % | $ 12.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Anika Therapeutics
ANIK
|
$ 14.91 | -1.52 % | $ 214 M | Nasdaq Global Select Market,SPB | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.39 | 2.11 % | $ 5.58 M | NYSE American | Israel |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.55 | 2.65 % | $ 182 M | Nasdaq Global Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 20.77 | 1.47 % | $ 2.64 B | Nasdaq Global Select Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.